Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer

Clinical Cancer Research

Volumn 7, Issue 12 SUPPL., 2001, Pages

  Kurokawa, H ^a   Arteaga, C L ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTIESTROGEN; CANERTINIB; CYCLIC AMP; DOPAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; HISTONE ACETYLTRANSFERASE; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; PELITINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; TAMOXIFEN; UNCLASSIFIED DRUG;

BREAST CANCER; CONFERENCE PAPER; DNA RESPONSIVE ELEMENT; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTOR CROSS-TALK; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 0035664786     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (56)

1. Nuclear receptor regulators: Cellular and molecular biology
2. Cloning of a novel estrogen receptor expressed in rat prostate and ovary
3. Functional domains of the human oestrogen receptor
4. The transcription activating function located in the hormone-binding domain of the estrogen receptor is not encoded by a single exon
5. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions
6. Nuclear receptor coactivators and corepressors
7. Analysis of estrogen receptor function in vitro reveals distinct classes of antiestrogens
8. The partial agonistic activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N/CoR and SMRT
9. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes
10. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen
11. Tamoxifen resistant breast cancer: Coregulators determine the direction of transcription by antagonist-occupied steroid receptors
12. Combinatorial roles of the nuclear receptor corepressor in transcription and development
13. Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: Antiestrogen selectivity and promoter dependence
14. Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone
15. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells
16. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic AMP, and insulin-like growth factor-I
17. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
18. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation
19. Phosphatidylinositol 3-kinase/Akt-mediated activation of estrogen receptor α: A new model for anti-estrogen resistance
20. Potentiation of estrogen receptor activation function 1 (AF-1) by Src/JNK through a serine 118-independent phosphorylation
21. MEKK1 activation of human estrogen receptor α and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells
22. The SMRT corepressor is regulated by a MEK-1 kinase pathway: Inhibition of corepressor function is associated with SMRT phosphorylation and nuclear export
23. Untangling the erbB signalling network
24. The erbB signaling network: Receptor heterodimerization in development and cancer
25. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
26. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells
27. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo
28. Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interactions with neu
29. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
30. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer
31. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer
32. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
33. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein
34. Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment
35. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy
36. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
37. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group Study
38. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer
39. A metanalysis of the interaction between HER2 and the response to endocrine therapy in metastatic breast cancer
40. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody
41. Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2
42. Kp1 and cyclin D1 through multiple signaling pathways
43. Hyperactivation of MAPK induces loss of ER expression in breast cancer cells
44. Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: Evidence for a role of EGFR in breast cancer growth and progression
45. Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells
46. Epidermal growth factor-related peptides and their receptors in human malignancies
47. The EGFR-selective tyrosine kinase inhibitor ZD1839 ("Iressa") is an effective inhibitor of tamoxifen-resistant breast cancer growth
48. Development of inhibitors for protein tyrosine kinases
49. Tyrosine kinase inhibitors. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido(3,2d)pydmidine-6-acrylamides bearing additional solubilizing functions
50. Selective inhibition of heregulin-dependent tyrosine phosphorylation and cellular signaling through erbB2, erbB3 and erbB4 by PD158780 and a new irreversible inhibitor PD183805
51. ZD1839 ("Iressa") as an anticancer agent
52. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase
53. Combinatorial chemoprevention of intestinal neoplasia
54. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
55. GW2016, a dual inhibitor of erbB-2 and EGFR tyrosine kinases: Effects on receptor tyrosine autophosphorylation, downstream signaling intermediaries and in vivo antitumor activity
56. Small molecule EGF receptor tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2/neu (erbB-2) overexpressing breast tumor cells in vitro and in vivo